Novel CAR Technology To Transform Cancer Therapy
Credit: iStock
Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.
However, collecting T cells is costly and time-consuming, CAR T-cell therapies have limited effectiveness in treating solid tumors and CAR T cells struggle to penetrate the tumor microenvironment.
This whitepaper explores the benefits of developing CAR therapies using alternative immune cell types.
Download this whitepaper to learn more about:
- CAR molecule design
- The safety advantages of CAR natural killer cells
- Developments in macrophage-based therapies
Brought to you by
Access This Whitepaper for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
